These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20553434)

  • 1. Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization.
    Romeo A; Chierichini A; Spagnoli A; Vittori M; Vacca M; Gozzer M; Spadea A; Anaclerico B; Dessanti ML; D'Andrea M; Toglia G; Annino L; Petti MC; Mengarelli A; Arcese W;
    Transfusion; 2010 Nov; 50(11):2432-46. PubMed ID: 20553434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone.
    Karanth M; Chakrabarti S; Lovell RA; Harvey C; Holder K; McConkey CC; McDonald D; Fegan CD; Milligan DW
    Bone Marrow Transplant; 2004 Sep; 34(5):399-403. PubMed ID: 15273706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
    Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
    Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study on single-dose rhG-CSF combined with chemotherapy in autologous peripheral blood stem cell transplantation].
    Tian H; Zhou SY
    Ai Zheng; 2002 Aug; 21(8):896-9. PubMed ID: 12478902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
    Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
    Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation.
    Singhal S; Powles R; Kulkarni S; Treleaven J; Sirohi B; Millar B; Shepherd V; Saso R; Rowland A; Long S; Cabral S; Horton C; Mehta J
    Bone Marrow Transplant; 2000 Mar; 25(5):501-5. PubMed ID: 10713626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
    Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of the addition of methylprednisolone to intermediate-dose cyclophosphamide and lenograstim for stem cell mobilization to make the timing of PBSC harvesting more predictable.
    Rudin CE; Melhuish J; Hall J
    Bone Marrow Transplant; 2007 Aug; 40(3):293-4. PubMed ID: 17529998
    [No Abstract]   [Full Text] [Related]  

  • 11. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex.
    Zhang C; Chen X; Zhang X; Gao L; Kong P; Wang Q; Peng X; Liu H
    Transfus Apher Sci; 2008 Aug; 39(1):21-8. PubMed ID: 18599353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim.
    Martino M; Console G; Irrera G; Callea I; Condemi A; Dattola A; Messina G; Pontari A; Pucci G; Furlò G; Bresolin G; Iacopino P; Morabito F
    J Clin Apher; 2005 Oct; 20(3):129-36. PubMed ID: 15892086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
    Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
    Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
    Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
    Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses.
    Suh C; Kim HJ; Kim SH; Kim S; Lee SJ; Lee YS; Kim EK; Kim SB; Lee JS; Kim MW; Kim K; Yoon SS
    Transfusion; 2004 Apr; 44(4):533-8. PubMed ID: 15043569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study.
    Basara N; Schmetzer B; Blau IW; Bischoff M; Günzelmann S; Kirsten D; Fauser AA
    Bone Marrow Transplant; 2000 Feb; 25(4):371-6. PubMed ID: 10723579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial.
    Schmitz N; Ljungman P; Cordonnier C; Kempf C; Linkesch W; Alegre A; Solano C; Simonsson B; Sonnen R; Diehl V; Fischer T; Caballero D; Littlewood T; Noppeney R; Schafhausen P; Jost L; Delabarre F; Marcus R
    Bone Marrow Transplant; 2004 Dec; 34(11):955-62. PubMed ID: 15489865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors.
    Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Flandrois G; Devys A; Stocco V; Cesbron A; Dehaut F; Moreau P; Harousseau JL; Mohty M
    Bone Marrow Transplant; 2009 Nov; 44(9):613-5. PubMed ID: 19308036
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.